CA2396037A1 - Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere - Google Patents

Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere Download PDF

Info

Publication number
CA2396037A1
CA2396037A1 CA002396037A CA2396037A CA2396037A1 CA 2396037 A1 CA2396037 A1 CA 2396037A1 CA 002396037 A CA002396037 A CA 002396037A CA 2396037 A CA2396037 A CA 2396037A CA 2396037 A1 CA2396037 A1 CA 2396037A1
Authority
CA
Canada
Prior art keywords
peptide
polymer
poly
release
samples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396037A
Other languages
English (en)
Inventor
Joachim B. Kohn
Deborah M. Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396037A1 publication Critical patent/CA2396037A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une formulation contenant un composé biologiquement actif ayant une structure dotée de sites de liaison hydrogène, qui est mélangé à un polymère ayant une structure dotée de sites de liaison hydrogène complémentaires, le polymère formant des produits de dégradation hydrolytiques qui favorisent la libération du composé biologiquement actif du polymère.
CA002396037A 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere Abandoned CA2396037A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US60/174,137 1999-12-31
PCT/US2001/000030 WO2001049249A2 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Publications (1)

Publication Number Publication Date
CA2396037A1 true CA2396037A1 (fr) 2001-07-12

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396037A Abandoned CA2396037A1 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Country Status (5)

Country Link
EP (1) EP1263453A4 (fr)
JP (1) JP2003519164A (fr)
AU (1) AU784226B2 (fr)
CA (1) CA2396037A1 (fr)
WO (1) WO2001049249A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251864A4 (fr) * 1999-12-31 2006-02-22 Univ Rutgers Formulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
CA2609053C (fr) 2005-05-17 2017-04-25 Sarcode Corporation Compositions et procedes pour le traitement des troubles oculaires
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
EP2114298B1 (fr) 2006-02-08 2022-10-19 Medtronic, Inc. Prothèses de type treillis temporairement raidies
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
JP2010508915A (ja) 2006-11-06 2010-03-25 タイレックス・ファーマ・インコーポレイテッド 埋込型医療機器のためのメッシュパウチ
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
CA2682190C (fr) 2007-03-29 2015-01-27 Tyrx Pharma, Inc. Enveloppes polymeres biodegradables pour implants mammaires
WO2008137807A1 (fr) 2007-05-02 2008-11-13 Tyrx Pharma, Inc. Polymères de dihydroxybenzoate et leurs utilisations
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP3797775A1 (fr) 2007-10-19 2021-03-31 Novartis AG Compositions et procédés pour le traitement de la rétinopathie diabétique
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5671463B2 (ja) 2008-09-22 2015-02-18 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． アミノフェノールエステルからの直鎖ポリエステルアミド
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
EP2437724B1 (fr) * 2009-06-01 2015-09-30 Tyrx, Inc. Compositions et méthodes pour prévenir les infections de blessures sternales
US9080015B2 (en) * 2009-07-31 2015-07-14 Rutgers, The State University Of New Jersey Biocompatible polymers for medical devices
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
AU2011293344B2 (en) 2010-08-25 2015-07-30 Medtronic, Inc. Novel medical device coatings
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012064963A1 (fr) 2010-11-12 2012-05-18 Tyrx, Inc. Dispositifs d'ancrage comprenant un principe pharmaceutique actif
US9381281B2 (en) 2011-07-20 2016-07-05 Tyrx, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
MX2015001098A (es) 2012-07-25 2015-09-25 Sarcode Bioscience Inc Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014137454A1 (fr) 2013-03-07 2014-09-12 Tyrx, Inc. Procédés et compositions permettant d'inhiber l'assemblage de cellules microbiennes se liant de façon irréversible à la surface de dispositifs médicaux
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP3054969B1 (fr) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles induits par les opioïdes
WO2015069305A1 (fr) 2013-11-08 2015-05-14 Tyrx, Inc. Compositions antimicrobiennes et procédés de prévention d'infection dans des sites d'incision chirurgicale
WO2016020308A1 (fr) * 2014-08-04 2016-02-11 Janssen Sciences Ireland Uc Forme posologique solide comprimée
CA3009814A1 (fr) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations et methodes pour traiter la rectocolite hemorragique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
WO1998036013A1 (fr) * 1997-02-18 1998-08-20 Rutgers, The State University Monomeres derives d'acides hydroxyliques et polymeres prepares a partir de ceux-ci
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
ZA9811377B (en) * 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
JP4312384B2 (ja) * 1998-04-13 2009-08-12 ラットガーズ ザ ステイト ユニヴァーシティ コポリマーライブラリーの構築
AU2373200A (en) * 1999-02-05 2000-08-25 Alien Technology Corporation Apparatuses and methods for forming assemblies

Also Published As

Publication number Publication date
JP2003519164A (ja) 2003-06-17
AU2925501A (en) 2001-07-16
WO2001049249A2 (fr) 2001-07-12
AU784226B2 (en) 2006-02-23
EP1263453A2 (fr) 2002-12-11
WO2001049249A3 (fr) 2002-01-17
EP1263453A4 (fr) 2008-02-20

Similar Documents

Publication Publication Date Title
AU784226B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
US7521061B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
AU775905B2 (en) Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
Tabata et al. Controlled delivery systems for proteins using polyanhydride microspheres
Kim et al. Polymeric drug delivery systems
Ulbrich et al. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release
Ruiz et al. Microencapsulation of peptide: a study of the phase separation of poly (D, L-lactic acid-co-glycolic acid) copolymers 50/50 by silicone oil
Sharma et al. Hydrogels: from simple networks to smart materials—advances and applications
Ranade Drug delivery systems: 3A. Role of polymers in drug delivery
Asai et al. In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogel
Acosta et al. Tramadol Release from a Delivery System Based on Alginate‐Chitosan Microcapsules
Schachter et al. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides
CA3086992C (fr) Materiau de depart pour medicament en vrac ou additifs pour medicament, et medicament en vrac ou medicament le contenant
USRE28316E (en) Entrapment compositions and processes
Jeong et al. Biodegradable polymeric drug delivery systems
Gwon et al. New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers
Gautier et al. Poly (L-Lysine Citramide), a water-soluble bioresorbable carrier for drug delivery: Aqueous solution properties of hydrophobized derivatives
Sparer Controlled release of drugs from glycosaminoglycan drug complexes
CN1476325B (zh) 活性物质的输送系统和活性物质的保护和施用方法
Jeong et al. Hydrogels for oral administration
Rypáček et al. Self-Degradable Hydrogel with Covalently Bound Proteolytic Enzyme
JP5650527B2 (ja) 活性成分の徐放システムおよび調製方法
Ye et al. The properties of polyesteramide and the effects on the stability of bovine serum albumin
Markland Modified polypeptides and polypeptide hydrogels for controlled drug delivery
Park et al. Hydrogels for Drug Delivery System:-Colon-Specific Delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140929